Renoprotective Effects of Losartan in CKD Stage 3
Benefits of Losartan in CKD Stage 3
- Angiotensin II receptor blockers (ARBs) like losartan are recommended for patients with CKD and albuminuria to slow kidney disease progression, according to the Kidney International guidelines 1, 3
- The American College of Cardiology recommends losartan for patients with CKD stage 3 and albuminuria to provide renoprotective effects 2
Dosing and Monitoring Recommendations
- The Kidney International guidelines recommend monitoring serum creatinine and potassium levels within 2-4 weeks after initiation or dose increase of losartan in CKD patients 3, 4
- The Annals of Internal Medicine guidelines suggest continuing losartan therapy unless serum creatinine rises by more than 30% within 4 weeks following initiation or dose increase 3, 4
Precautions and Monitoring
- The American College of Cardiology warns of a risk of acute renal failure in patients with severe bilateral renal artery stenosis taking losartan 2
- The Kidney International guidelines recommend considering reducing the dose or discontinuing losartan if the patient develops symptomatic hypotension, uncontrolled hyperkalemia despite treatment, or acute kidney injury 3
Combination Therapy Considerations
- The American College of Cardiology and the Annals of Internal Medicine guidelines advise against using losartan in combination with ACE inhibitors or direct renin inhibitors due to increased risk of adverse effects 2, 4
Special Populations
- The Diabetes Care guidelines strongly recommend RAS inhibitors like losartan for patients with diabetes and CKD with albuminuria 5